$6.24
7.00% yesterday
Nasdaq, Apr 03, 10:00 pm CET
ISIN
US45257U1088
Symbol
IMNM
Sector
Industry

Immunome Inc Stock price

$6.24
-2.70 30.20% 1M
-7.19 53.54% 6M
-4.38 41.24% YTD
-15.36 71.11% 1Y
+0.47 8.15% 3Y
-7.21 53.61% 5Y
-7.21 53.61% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.47 7.00%
ISIN
US45257U1088
Symbol
IMNM
Sector
Industry

Key metrics

Market capitalization $542.57m
Enterprise Value $330.10m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 36.52
P/S ratio (TTM) P/S ratio 60.02
P/B ratio (TTM) P/B ratio 2.22
Revenue growth (TTM) Revenue growth -35.50%
Revenue (TTM) Revenue $9.04m
EBIT (operating result TTM) EBIT $-271.72m
Free Cash Flow (TTM) Free Cash Flow $-117.97m
Cash position $217.30m
EPS (TTM) EPS $-5.18
P/E forward negative
P/S forward 279.47
EV/Sales forward 170.03
Short interest 11.38%
Show more

Is Immunome Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Immunome Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Immunome Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Immunome Inc forecast:

Buy
100%

Financial data from Immunome Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
9.04 9.04
36% 36%
100%
- Direct Costs 2.10 2.10
188% 188%
23%
6.94 6.94
48% 48%
77%
- Selling and Administrative Expenses 31 31
64% 64%
341%
- Research and Development Expense 246 246
138% 138%
2,718%
-270 -270
148% 148%
-2,983%
- Depreciation and Amortization 2.10 2.10
188% 188%
23%
EBIT (Operating Income) EBIT -272 -272
148% 148%
-3,006%
Net Profit -293 -293
174% 174%
-3,241%

In millions USD.

Don't miss a Thing! We will send you all news about Immunome Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunome Inc Stock News

Neutral
Business Wire
about one hour ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 12:45 p.m. Eastern Time. Interested parties can access the liv...
Neutral
Business Wire
about 17 hours ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchas...
Neutral
Business Wire
16 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update. “Immunome's efficient execution in 2024 laid the foundation for a productive 2025,” said Clay B. Siegall, Ph.D., Presid...
More Immunome Inc News

Company Profile

Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

Head office United States
CEO Clay Siegall
Employees 118
Founded 2006
Website www.immunome.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today